share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/08/16 16:08

Moomoo AI 已提取核心訊息

Transcode Therapeutics received two deficiency notices from Nasdaq on August 13 and 15, 2024. The first notice cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 through August 12. Due to two previous reverse stock splits, the company is not eligible for the standard 180-day compliance period.The second notice indicated non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported stockholders' equity of $1.32 million in Q2 2024. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma stockholders' equity to $3.7 million, there is no assurance Nasdaq will consider this adjustment.Transcode plans to request a hearing before the Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action. The panel will consider both deficiencies during the hearing. The company must submit its hearing request regarding the stockholders' equity requirement by August 22, 2024, if it regains compliance with the minimum bid price requirement before then.
Transcode Therapeutics received two deficiency notices from Nasdaq on August 13 and 15, 2024. The first notice cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 through August 12. Due to two previous reverse stock splits, the company is not eligible for the standard 180-day compliance period.The second notice indicated non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported stockholders' equity of $1.32 million in Q2 2024. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma stockholders' equity to $3.7 million, there is no assurance Nasdaq will consider this adjustment.Transcode plans to request a hearing before the Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action. The panel will consider both deficiencies during the hearing. The company must submit its hearing request regarding the stockholders' equity requirement by August 22, 2024, if it regains compliance with the minimum bid price requirement before then.
Transcode Therapeutics於2024年8月13日和15日收到了納斯達克發出的兩份缺陷通知。第一份通知指出,從7月1日到8月12日,該公司未能保持連續30個交易日的最低1.00美元買盤價要求。由於之前進行了兩次拆股並股,該公司不符合標準的180天合規期。第二份通知顯示,該公司未能滿足最低股東權益要求250萬美元,因爲在2024年第二季度公司報告的股東權益爲132萬美元。儘管2024年7月的股權發行增加了約240萬美元的淨收益,使得形式上股東權益達到370萬美元,但納斯達克不一定會考慮此調整。Transcode計劃向納斯達克聽證委員會請求一次聽證會,這將自動暫停任何暫停或退市的行動。委員會將在聽證會上考慮這兩個缺陷。公司必須在2024年8月22日之前提交關於股東權益要求的聽證請求,前提是公司在此之前已恢復對最低買盤價要求的合規。
Transcode Therapeutics於2024年8月13日和15日收到了納斯達克發出的兩份缺陷通知。第一份通知指出,從7月1日到8月12日,該公司未能保持連續30個交易日的最低1.00美元買盤價要求。由於之前進行了兩次拆股並股,該公司不符合標準的180天合規期。第二份通知顯示,該公司未能滿足最低股東權益要求250萬美元,因爲在2024年第二季度公司報告的股東權益爲132萬美元。儘管2024年7月的股權發行增加了約240萬美元的淨收益,使得形式上股東權益達到370萬美元,但納斯達克不一定會考慮此調整。Transcode計劃向納斯達克聽證委員會請求一次聽證會,這將自動暫停任何暫停或退市的行動。委員會將在聽證會上考慮這兩個缺陷。公司必須在2024年8月22日之前提交關於股東權益要求的聽證請求,前提是公司在此之前已恢復對最低買盤價要求的合規。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息